Literature DB >> 33172545

[Pharmacogenomics: precision tool in routine prescription].

Bing Yu1.   

Abstract

Pharmacogenomics is an emerging tool to improve the efficacy and safety of drug treatment through the DNA analysis in the genes related to drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics). Clinicians need to integrate the genomic data in their benefit-risk assessment and then provide the right drug to the right patient at the right time. This tool can help to prevent an ineffective treatment, select right dose and reduce adverse drug reactions that are common in the current practice under the trial-observation-adjustment model. Pharmacogenomics may have extensive impacts on unique paediatric patients to enhance a better relationship between medical professionals and affected children or their guardians and to improve the drug compliance. Clinicians should embrace the advancements in pharmacogenomics and actively participate in clinical research to identify the ancestor-related alleles and develop the population-specific gene panel. It will allow patients to enjoy more achievements in pharmacogenomics by implementing it in first line clinical practice.

Entities:  

Year:  2020        PMID: 33172545      PMCID: PMC7666388     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  32 in total

1.  Codeine, ultrarapid-metabolism genotype, and postoperative death.

Authors:  Catherine Ciszkowski; Parvaz Madadi; Michael S Phillips; Albert E Lauwers; Gideon Koren
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

Review 2.  Developmental Changes in Pharmacokinetics and Pharmacodynamics.

Authors:  John van den Anker; Michael D Reed; Karel Allegaert; Gregory L Kearns
Journal:  J Clin Pharmacol       Date:  2018-10       Impact factor: 3.126

3.  Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.

Authors:  Mary V Relling; Matthias Schwab; Michelle Whirl-Carrillo; Guilherme Suarez-Kurtz; Ching-Hon Pui; Charles M Stein; Ann M Moyer; William E Evans; Teri E Klein; Federico Guillermo Antillon-Klussmann; Kelly E Caudle; Motohiro Kato; Allen E J Yeoh; Kjeld Schmiegelow; Jun J Yang
Journal:  Clin Pharmacol Ther       Date:  2019-01-20       Impact factor: 6.875

Review 4.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.

Authors:  Stephen G Gonsalves; Robert T Dirksen; Katrin Sangkuhl; Rebecca Pulk; Maria Alvarellos; Teresa Vo; Keiko Hikino; Dan Roden; Teri E Klein; S Mark Poler; Sephalie Patel; Kelly E Caudle; Ronald Gordon; Barbara Brandom; Leslie G Biesecker
Journal:  Clin Pharmacol Ther       Date:  2019-01-24       Impact factor: 6.875

Review 5.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

6.  Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

Authors:  Roelof W F van Leeuwen; Robert Peric; Koen G A M Hussaarts; Emma Kienhuis; Nikki S IJzerman; Peter de Bruijn; Cor van der Leest; Henk Codrington; Jeroen S Kloover; Bronno van der Holt; Joachim G Aerts; Teun van Gelder; Ron H J Mathijssen
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

7.  Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.

Authors:  Eva Kereszturi; Zsanett Tarnok; Emese Bognar; Krisztina Lakatos; Luca Farkas; Julia Gadoros; Maria Sasvari-Szekely; Zsofia Nemoda
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

8.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.

Authors:  S L Van Driest; Y Shi; E A Bowton; J S Schildcrout; J F Peterson; J Pulley; J C Denny; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2013-11-19       Impact factor: 6.875

9.  Frequency of CYP2D6 Alleles Including Structural Variants in the United States.

Authors:  Andria L Del Tredici; Alka Malhotra; Matthew Dedek; Frank Espin; Dan Roach; Guang-Dan Zhu; Joseph Voland; Tanya A Moreno
Journal:  Front Pharmacol       Date:  2018-04-05       Impact factor: 5.810

10.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

Authors:  J A Johnson; K E Caudle; L Gong; M Whirl-Carrillo; C M Stein; S A Scott; M T Lee; B F Gage; S E Kimmel; M A Perera; J L Anderson; M Pirmohamed; T E Klein; N A Limdi; L H Cavallari; M Wadelius
Journal:  Clin Pharmacol Ther       Date:  2017-04-04       Impact factor: 6.875

View more
  1 in total

1.  Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China.

Authors:  Dandan Li; Linna Peng; Shishi Xing; Chunjuan He; Tianbo Jin
Journal:  BMC Genom Data       Date:  2021-11-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.